Summary Report of Consolidated Financial Results
For the Six Months Period ended September 30, 2012
November 9, 2012stCompany name: NIPRO CORPORATION
TSE/OSE-1 section
Code No.8086
URL: http://www.nipro.co.jp/
Representative: Yoshihiko Sano, President and Representative Director
Contact person: Akihiko Yamabe, Director and General Manager of Accounting Division
TEL: (06)6372-2331
Filling date of quarterly reporting: November 14, 2012
Payment date of cash dividends: December 10, 2012
Supplemental material on quarterly reporting: Yes
Presentation on quarterly results: Yes (for institutional investors and analysts)(Note: Amounts are truncated to one million yen)
1. Consolidated Results for the Six Months ended September 30, 2012 (From April 1, 2012 to September 30, 2012)(1) Consolidated Results of Operations(Note: % of change from the same period a year ago)
Net Sales
Operating Income
Ordinary Income
Net Income
Millions of yen
6 months ended September 30, 2012
6 months ended September 30, 2011

117,280
102,432%

Millions of yen

14.5
8.2

6,303
8,168

%

(22.8)(9.6)

Millions of yen%

Millions of yen

4,845
5,121

(5.4)
(6.4)

6,608
457

%

(81.5)

Note: Comprehensive income 6 months ended September 30, 2012: (5,404) million yen (-%) 6 months ended September 30, 2011: (15,697)
million yen (-%)

Earnings per Share
6 months ended September 30, 2012
6 months ended September 30, 2011

Diluted Earnings per Share

Yen

Yen

38.75
3.61

34.95
3.16

(2) Consolidated Financial Position
Total Assets

Net Assets

Millions of yen

Millions of yen

6 months ended September 30, 2012
Year ended March 31, 2012

Note: Equity2.

512,057
499,686

6 months ended September 30, 2012: 102,201 million yen

Equity Ratio%

109,108
113,950

20.0
22.0Year ended March 31, 2012: 109,820 million yen

Dividends

Year ended March 31, 2012
Year ending March 31, 2013
Year ending March 31, 2013
(Forecast)First-quarter
Yen-

Annual Dividends per Year
Year-end Dividends
Second-quarter
Third-quarter
Yen
Yen
Yen
12.00
11.50
12.00
-

8.50

Annual Dividends

Yen
23.50
20.50

Note: Revisions to the forecast of cash dividends in the current quarter: Yes
3. Forecast of Consolidated Financial Results for the Year ending March 31, 2013 (From April 1, 2012 to March 31, 2013)(Note: The % displays in the line of year ending March 31, 2013 show increase/decrease ratio against the year ended March
31, 2012)
OperatingEarnings
Net Sales
Ordinary Income
Net Income
Incomeper Share
Millions of yen%
Millions of yen%
Millions of yen%
Millions of yen%
Yen
Year ending March 31, 2013
241,000 13.7 13,500(14.7)
11,500
(4.0)
9,750
112.6
57.17
Note: Revisions to the forecast of consolidated financial results in the current quarter: Yes

*Notes(1) Change in Significant Subsidiaries during the Current Period(Change in specified subsidiaries caused a change in the scope of consolidation): No
Additional: 0Removal: 0(2) Adoption of Accounting Treatments Simplified or Unique for Preparation: No(3) Change in Accounting Policies and Accounting Estimate and Restatement[1] Changes in accounting policies by a newly issued accounting pronouncement: Yes[2] Changes other than [1]: No[3] Change in accounting estimate: Yes[4] Restatement: No
Note: Depreciation method was changed from the first-quarterly result, which is applied to “Changes in accounting
policies which are difficult to distinguish from changes in accounting estimates”. Detailed information can be found in
P.4 “2. Summary Information (3) Change in Accounting Policies and Accounting Estimate and Restatement” in theattachment.
(4) Issued Shares (Common stock)[1] Number of issued shares at end of the period (including treasury stock):
6 months ended September 30, 2012
: 171,459,479 sharesYear ended March 31, 2012
: 171,459,479 shares[2] Number of treasury stock at end of the period:
6 months ended September 30, 2012
: 913,671 sharesYear ended March 31, 2012
: 913,612 shares[3] Average number of shares during the period :6 months ended September 30, 2012
: 170,545,858 shares
6 months ended September 30, 2011
: 126,843,790 shares*Information regarding the quarterly review procedure
This quarterly summary report is exempt from quarterly review procedure based on the Financial Instruments
and Exchanges Act. It is under the review procedure process at the time of disclosure of this report.
*Disclaimer regarding projection information including appropriate use of forecasted financial result, and otherspecial notes
The projection figures shown above are based on information that was available at the time of preparation and may
contain certain uncertainties. Actual performance and other factors may differ from these projections due tochanges in circumstances and other developments. More information concerning these forecasts can be found in P.3“1. Qualitative Information for the Six Months Period ended September 30, 2012, (3) Qualitative Information
Concerning Forecast of Consolidated Financial Results” in the attachment.

Table of Contents

1.

2.

3.

Qualitative Information for the Six Months Period ended September 30, 20122(1) Qualitative Information Concerning Consolidated Financial Results2(2) Qualitative Information on the Consolidated Financial Position

3(3) Qualitative Information Concerning Forecast of Consolidated Financial Results3

Summary (Other) Information

3(1) Overview of Changes in Significant Consolidated Subsidiaries

3(2) Overview of Accounting Procedure Unique for Preparation of Quarterly Consolidated Financial Statement3(3) Overview of Changes in Accounting Policies and Accounting Estimate and Restatement

4

Consolidated Financial Statements

5(1) Quarterly Consolidated Balance Sheets

5(2) Quarterly Consolidated Statements of Income andQuarterly Consolidated Statements of Comprehensive Income

7

Quarterly Consolidated Statements of Income

7

Quarterly Consolidated Statements of Comprehensive Income7(3) Quarterly Consolidated Statement of Cash Flows

8(4) Notes Related to Going Concern

10(5) Segment Information

10(6) Notes to Statements of Shareholders’ Equity, If Having Significant Variation

11

-1-

1.

Qualitative Information for the Six Months Period ended September 30, 2012

(1) Qualitative Information Concerning Consolidated Financial Results
In the current quarter period under review (quarter ended September 30, 2012), uncertain outlook for the global
economy prevailed because the economic stagnation caused by debt crisis has continued in Europe even though
American economy showed gradual recovery thanks to an increase of personal consumption based on the progress ofhousehold debt adjustment and housing market improvement.
Japanese economy, on the other hand, was slowly recovering with the demand for reconstruction from Great East
Japan Earthquake but still under harsh management condition due to flagging export with deceleration of overseas
economy and the fixed strong yen.
Under such situation, the Nipro Group continued to work hard to improve our manufacturing and sales bases andincrease our sales.
As a result, the consolidated sales in the six-months of fiscal year 2012 increased 14.5% from the same period of theprevious year to 117,280 million yen.
As for the profit, consolidated operating income decreased 22.8% from the same period of the previous year to 6,303
million yen because of an increase in selling, general and administrative expenses, and consolidated ordinary income
decreased 5.4% from the same period of the previous year to 4,845 million yen due to foreign exchange losses.
However, the consolidated net income increased 1,343.5% to 6,608 million yen due to generation of proceeds for salesof investment securities and a decrease in extraordinary losses.
The overviews of the results by segment in the current period are as follows.
[1] Medical BusinessLooking at the domestic market, business conditions remained extremely severe because the market competition was
intensified due to the effect of revision of medical treatment fee conducted in this April and the reduction of official
prices for drugs and medical materials. However, each product group recorded great sales as a result of our aggressive
sales activities and improvement of sales efficiency aiming to increase our global share.
Our medical-equipment-related products such as dialysis system and our dialysis-related products such as HDF filter,blood circuits and dialysis pharmaceuticals showed strong growth. The sales of our testing-related products such as
glucose analysis device (POCT) and vacuum blood drawing system, enteral-alimentation-related products andinjection-transfusion-related products also steadily increased.
Overseas sales, on the other hand, have been affected seriously by appreciation of the yen against the US dollar andeuro in the foreign exchange markets, but the sales of dialysis-related products such as dialyzer and system test fordiabetes mellitus showed significant increase as a result of our promotion of detailed sales activities for dialysis-related
and diabetes-related products in close to medical front. As for the sales expansion, we established new sales base in
Myanmar, where the future demand is expected, this June. This September, we acquired Salbego Laboratorio
Farmaceutico Ltda, a dialysate manufacturer in Brazil, so as to promote sales activities in dialysis market with a good
selection of dialysis products. In addition, India plant started manufacturing from this October, and plants in Indonesia
and Bangladesh also proceed the preparation for operation. Under these situations, we will work harder to promote theestablishment of our brand image and reinforce our sales system.
As a result, net sales of this business increased 15.6% from the same period of the previous year to 81,380 million
yen.
[2] Pharmaceutical BusinessThis business consists of two main divisions: the Generic Drugs Division, providing low cost and high quality medical
drugs, and the Contracted Manufacturing Division, offering high value-added products to meet customer needs.
Sales of generic drugs are expected to grow in line with the market, due in part to a government policy for the
dissemination of the market for generic drugs to over 30% by the end of fiscal year 2012. Consequently a number ofpolicies have been implemented to encourage the use of generic products. Major pharmaceutical manufacturers havemade a full-scale entry into the Japanese market and foreign generic manufacturers have strengthened their marketingstrategies, making the competitive environment surrounding the domestic market more severe.
Under these conditions, we have tried to increase the share of the oral drug through reinforcing our sales promotions
to dispensing pharmacies and by the close co-operation with drug wholesalers. In addition, as a result of our detailed
information service provided mainly to large hospital, the sales in the current period exceeded the sales in the same
period of the previous year.
Looking at sales of our contracted manufacturing business, we have worked hard at realizing a variety of detailed
services such as contracted development and supporting high value-added initiatives other than OEM manufacturing ofother companies’ brand. Contracted sales of generic drugs showed fine growth so that the sales grew steadily in thisquarter.
As a result, net sales of this business increased 21.3% from the same period of the previous year to 22,989 million
yen.
[3] Materials Business
The sales of material glass tube for ampoule and material glass tube for tube bottles increased from the same periodof the previous year thanks to the enforcement of the sales to foreign countries. However, the domestic sales
decreased from the same period of the previous year with order decrease because the save electricity campaign in thissummer decreased the plant operating hours of domestic processing manufacturers. We also received less order fortube bottles and the sales result remained roughly flat.
Pharmaceutical glass business in China recorded fine growth compared to the same period of the previous year as aresult of capital investment and promotion of sales activities. The sales of glass for thermos bottles had grown steadily
thanks to the increased demand of glass thermos bottles after the Great East Japan Earthquake, but the demand was
getting decreased and the sales decreased as well. As for glass for lighting purpose, the order for material glass tube

-2-

for electric lamp decreased due to the decreased operation of domestic automotive manufacturers and also the lineup
of electric lamp production was diminished so the sales of glass for lighting purpose decreased from the same period of
the previous year.
In the field of pharmaceutical containers, the sales of bags for antimicrobial agent and pre-filled syringes increased
steadily as well as rubber stoppers for pharmaceutical and vaccine use and kit form containers.
As for the medical preparation and administration related device, the sales showed good increase with our system
suitable for each pharmaceuticals. These systems were provided by both of self- development and joint developmentwith pharmaceutical companies based on our processing techniques for plastics, metal and rubber in order to meet thediverse needs in the medical front. Furthermore, under the restrictive policy for medical cost, we continue to promote
contract manufacturing and development cooperating with domestic and foreign pharmaceutical companies in generallife cycle management of pharmaceuticals, which includes the development of combination products, systematization
for self-injection and modification of dosage form.
As a result, net sales of this business decreased 1.1% from the same period of the previous year to 12,793 million yen.

[4] Other BusinessIn the other business, the sales from real estate rental income decreased 14.8% from the same period of the previous
year to 116 million yen.

(2) Qualitative Information on the Consolidated Financial Position[1] Analysis concerning the conditions of assets, liabilities and net assets
Total assets increased 12,371 million yen from the end of the previous period to 512,057 million yen. Current assets
increased 6,746 million yen mainly due to an increase of 5,574 million yen in notes and accounts receivable-trade, andnoncurrent assets increased 5,625 million yen mainly due to an increase of 6,439 million yen in construction in progress.
Total liabilities increased 17,213 million yen from the end of the previous period to 402,949 million yen. Current liabilities
increased 4,678 million yen mainly due to an increase of 11,770 million yen in short-term loans payable, and noncurrent
liabilities increased 12,535 million yen mainly due to an increase of 11,134 million yen in long-term loans payable.
Total net assets decreased 4,841 million yen from the end of the previous period to 109,108 million yen. Shareholders’equity increased 4,464 million yen and accumulated other comprehensive income decreased 12,084 million yen.
[2] Condition of cash flow
The ending balance of cash and cash equivalents in the period under review increased 106 million yen from the previous
year to 79,556 million yen.
(Cash flows from operating activities)
Net cash provided by operating activities was 8,015 million yen. The main accounts of cash inflow were income before
income taxes and minority interests, 8,976 million yen and depreciation and amortization, 9,874 million yen. The main
accounts of cash outflow were the increase of trade notes and accounts receivable, 5,590 million yen and payment ofcorporate income tax, 2,987 million yen.
(Cash flows from investing activities)
Net cash used in investing activities was 18,694 million yen. The main accounts of cash outflow were payment into
time deposit, 11,094 million yen, and purchase of noncurrent assets, 15,441 million yen. The main account of cash
inflow was proceeds from withdrawal of time deposits, 14,279 million yen.
(Cash flows from financing activities)
Net cash provided by financing activities was 10,091 million yen. The main account of cash inflow was proceeds fromlong-term loans payable, 32,056 million yen. The main account of cash outflow was repayment of long-term loans
payable, 18,574 million yen.

(3) Qualitative Information Concerning Forecast of Consolidated Financial Results
As for the world economy in the future, economic stagnation is expected to be continued due to the bad effect from theanxiety about the protracted debt problem in Europe. The domestic economy, on the other hand, will also continue to besluggish because the capital investment and export will keep decreasing.
In such situation, we will aim to promote our sales performance with a huge selection and high-value added products.
At this moment, the forecast of consolidated financial results for the FY2012 which was published on August 10, 2012 isrevised based on the current movement in performance.

2.

Summary (Other) Information(1) Change in Significant Subsidiaries during the Current Period
N/A(2) Accounting Procedure Unique for Preparation of Quarterly Consolidated Financial Statements:
N/A

-3-

(3) Change in Accounting Policies and Accounting Estimate and Restatement(Changes in accounting policies which are difficult to distinguish from changes in accounting estimates)
Effective from the first quarter of the current fiscal year, the Company and its domestic subsidiaries changes thedepreciation method for the relevant tangible assets newly acquired from April 1, 2012 according to the amendment ofCorporation Tax Act in Japan.
As a result, consolidated operating income, consolidated ordinary income and consolidated net income increased by
140 million yen for each compared with the previous method.

-4-3. Consolidated Financial Statements(1) [ Quarterly Consolidated Balance Sheets](Amount: million yen)
As ofMarch 31, 2012
AssetsCurrent Assets
Cash and deposits
Notes and accounts receivable-trade
Merchandise and finished goods
Work in process
Raw materials and supplies
Deferred tax assets
Other
Allowance for doubtful accounts
Total current assets
Noncurrent assets
Property, plant and equipment
Bulidings and structures
Accumulated depreciation and impairment loss
Buildings and structures, net
Machinery, equipment and vehicles
Accumulated depreciation and impairment loss
Machinery equipment and vehicles, net
Land
Lease assets
Accumulated depreciation
Lease assets, net
Construction in progress
Other
Accumulated depreciation and impairment loss
Other, net
Total property, plant and equipment
Intangible assets
Goodwill
Lease assets
Other
Total intangible assets
Investments and other assets
Investment securities
Deferred tax assets
Other

As of
September 30, 2012

95,737
68,641
48,114
8,753
14,736
4,829
9,983
(360)
250,435

96,317
74,21649,582
9,231
15,716
4,435
8,030
(347)
257,182

116,878(63,320)
53,558142,067(103,263)
38,804
20,446
1,680
(735)
944
26,95728,317(23,350)
4,967
145,678

120,987(65,585)
55,402
150,359(109,811)
40,54821,555
1,987
(908)
1,079
33,396
29,578(24,031)
5,547
157,530

11,894305
6,950
19,151

11,230340
10,025
21,596

71,8296,597
8,954

54,56812,942
11,268

Allowance for doubtful accounts(2,961)(3,030)Total investments and other assets
Total noncurrent assets
Total assets

84,420249,250499,686

75,748254,875
512,057-5-

(Amount: million yen)
As ofMarch 31, 2012
Liabilities
Current liabilities
Notes and accounts payable-trade
Short-term loans payable
Commercial papers
Current portion of bonds
Lease obligations
Accounts payable-otherAccrued directors' bounuses
Income taxes payable
Provision for bounuses
Provision for directors' bounuses
Provision for loss on business liquidation
Notes payable-facilities
Other
Total current liabilities
Noncurrent liabilities
Bonds payable
Convertible bond-type bonds
with subscription right s to shares
Long-term loans payable
Lease obligations
Deferred tax liabilities
Provision for retirement benefits
Provision for directors' retirement benefits
Provision for loss on litigation
Other
Total noncurrent liabilities
Total liabilities
Net assets
Shareholders' equity
Capital stock
Capital surplus
Retained earnings
Treasury stock
Total shareholders' equity
Accumulated other comprehensive income
Valuation difference on available-for-sale securities
Foreign currency translation adjustment
Total accumulated other comprehensive income
Minority interests
Total net assets
Total liabilities and net assets

-6-

As of
September 30, 2012

37,721
104,131
10,00010,000
426
6,036
153
3,276
2,308
43
1,954
3,399
9,636
189,089

39,317
115,901－
10,000
728
6,374
－
2,518
2,360
122
1,954
3,249
11,240193,767

34,00034,00015,00015,000140,380
914
1,761
1,987
702
170
1,729
196,645
385,735

151,514
1,750
2,035
2,401
704
170
1,603
209,181402,949

84,397636
48,389(864)
132,558

84,397636
52,853(864)
137,022(6,528)(16,209)(22,737)
4,129
113,950499,686(17,878)(16,943)(34,821)
6,907
109,108
512,057

(2) [Quarterly Consolidated Statements of Income and Quarterly Consolidated Statement of Comprehensive Income]Quarterly Consolidated Statements of Income(Amount: million yen)
FY2011 first six months(From April 1, 2011
to September 30, 2011)
Net sales
Cost of sales
Gross profit
Selling, general and administrative expenses
Operating income
Non-operating income
Interest income
Dividends income
Other
Total non-operating income
Non-operating expenses
Interest expenses
Foreign exchange losses
Equity in losses of affiliates
Other
Total non-operating expenses
Ordinary income
Extraordinary income
Gain on sales of noncurrent assets
State subsidy
Gain on sales of investment securities
Other
Total extraordinary income
Extraordinary loss
Loss on retirement of noncurrent assets
Loss on valuation of investment securities
Loss on disaster
Company funeral expenses
Other
Total extraordinary losses
Income before income taxes and minority interests
Income taxes-current
Income taxes-deferred
Total income taxes
Income before minority interests
Minority interests in income
Net income

FY2012 first six months(From April 1, 2012
to September 30, 2012)

102,432
72,02130,411
22,243
8,168

117,280
84,86632,414
26,111
6,303

257
362
420
1,039

429
861
454
1,745

1,616
2,039
43
388
4,087
5,121

1,712
1,253
38
199
3,203
4,845

112
86
－
10
209

30
40
4,159
83
4,313

285
675
1,111
－
125
2,197
3,132
2,333
9
2,342
790
332
457

65
27
－
40
47
181
8,976
2,209
13
2,223
6,753
145
6,608

[Qarterly Consolidated Statements of Comprehensive Income](Amount: million yen)
FY2011 first six months(From April 1, 2011
to September 30, 2011)
Income before minority interests
Other comprehensive income
Valuation difference on available-for-sale securities
Foreign currency translation adjustment
Total other comprehensive income
Comprehensive income
Comprehensive income attributable to owners of the parent
Comprehensive income attributable to minority interests-7-

FY2012 first six months(From April 1, 2012
to September 30, 2012)

790

6,753

(15,666)(821)(16,488)(15,697)(16,013)315(11,351)(806)(12,158)(5,404)(5,477)72

(3) [ Quarterly Consolidated Statements of Cash Flows]
FY2011 first six months(From April 1, 2011
to September 30, 2011)
Net cash provided by (used in) operating activities
Income before income taxes and minority interests
Depreciation and amortization
Impairment loss
Amortization of goodwill
Equity in (earnings) losses of affiliates
Increase (decrease) in allowance for doubtful accounts
Interest and dividends income
Interest expenses
Foreign exchange losses (gains)
Loss (gain) on sales of investment securities
Decrease (increase) in notes and accounts receivable-trade
Decrease (increase) in inventories
Increase (decrease) in notes and accounts payable-trade
Decrease (increase) in other assets
Increase (decrease) in other liabilities
Other loss (gain)
SubtotalInterest and dividends income received
Interest expenses paid
Other proceeds
Other payments
Income taxes paid
Net cash provided by (use in) operating activities
Net cash provided by (used in) investing activities
Payments into time deposits
Proceeds from withdrawal of time deposits
Purchase of investment securities
Proceeds from sales of investment securities
Payments for sales of investments
in subsidiaries resulting in change in scope of consolidation
Payments for investments in capital
Purchase of noncurrent assets
Proceeds from sales of noncurrent assets
Payments for retirement of noncurrent assets
Proceeds from capital investment subsidies received
Net decrease (increase) in short-term loans receivable
Payments of loans receivableCollection of loans receivable
Other payments
Other proceeds
Net cash provided by (use in) investment activities-8-(Amount: million yen)
FY2012 first six months(From April 1, 2012
to September 30, 2012)

3,132
10,211
－
1,147
43
7
(619)
1,616
1,175
－
(4,061)(4,126)940(1,017)(2,949)
873
6,373
625
(1,567)130(147)(2,938)
2,475

8,976
9,874
1
1,408
38
54
(1,290)1,712
370(4,159)(5,590)(1,898)
1,379
958
(72)
20
11,784
1,044(1,706)101(221)(2,987)
8,015(7,162)
1,064(14,029)
10(11,094)
14,279(9,935)5,800(2,587)(2,105)－(12,102)
148
(5)
33
882
(708)
23
(75)
－
(34,511)(1,494)(15,441)
45
(13)
53
1,813
(680)
80
(0)
0
(18,694)

FY2011 first six months(From April 1, 2011
to September 30, 2011)
Net cash provided by (use in) financial activities
Net increase (decrease) in short-term loans payable
Increase (decrease) in commercial papers
Proceeds from long-term loans payable
Repayment of long-term loans payable
Proceeds from issuance of bonds
Proceeds from stock issuance to minority shareholders
Decrease (increase) in treasury stock
Repayments of finance lease obligations
Cash dividends paid
Cash dividends paid to minority shareholders
Net cash provided by (use in) financing activities
Effect of exchange rate change on cash and cash equivalents
Net increase (decrease) in cash and cash equivalents
Cash and cash equivalents at beginning of paid
Increase in cash and cash equivalentsfrom newly consolidated subsidiary
Cash and cash equivalents at end of period-9-(Amount: million yen)
FY2012 first six months(From April 1, 2012
to September 30, 2012)(3,975)－43,870(16,407)
979
－
(0)
(202)
(1,992)(4)
22,268(384)(10,152)
78,921

8,672(10,000)
32,056(18,574)
－
241
(0)
(340)
(1,953)(11)
10,091(229)(816)
79,4499,266

923

78,03579,556

(4) Notes Related to Going Concern
N/A(5) Segment InformationⅠ

FY2011 (From April 1, 2011 to September 30, 2011)

1.

Sales and Profit by Reportable Operating Segment(Millions of yen)Segment
MedicalPharmaceutical

Materials

Total

Other
(Note.1)

Total

Adjustment(Note.2)

Consolidated
Statements ofIncome(Note.3)

Net sales(1)Sales to third parties

70,414

18,95012,930102,295

137

102,432－

102,432(2)Inter-segment sales
and transfers

657

9,389

1,708

11,75422

11,777(11,777)－

Total

71,071

28,33914,639114,050

159

114,210(11,777)

102,432

Segment profit

8,386

2,110

1,289

11,786109

11,895(3,727)

8,168(Notes)
1.
2.

3.
2.

“Other” is the business segment which is not included in the segment and consist of real estate income and sales
by headquarter.
Adjustment for the segment profit of (3,727) million yen includes elimination of inter-segment transaction of (249)
million yen and corporate cost of (3,477) million yen. Corporate cost consisted primarily of general andadministrative expenses and research and development cost which do not belong to the reporting segment.
Segment profit is adjusted to the operating income on the consolidated statements of income.

Information about Impairment Loss on Fixed Assets and Goodwill by Reportable Operating Segment
N/A- 10 -

Ⅱ

FY2012 (From April 1, 2012 to September 30, 2012)

1.

Sales and Profit by Reportable Operating Segment(Millions of yen)Segment
MedicalPharmaceutical

Materials

Total

Other
(Note.1)

Total

Adjustment(Note.2)

Consolidated
Statements ofIncome(Note.3)

Net sales(1)Sales to third parties

81,38022,98912,793

117,163

116

117,280－

117,280(2)Inter-segment sales
and transfers

620

9,553

1,810

11,98422

12,007(12,007)－

Total

82,00032,543

14,604

129,148

139

129,287(12,007)

117,280

Segment profit

7,289

1,428

1,072

9,789

110

9,899

(3,596)6,303(Notes)1.
2.

3.

“Other” is the business segment which is not included in the segment and consist of real estate income and sales
by headquarter.
Adjustment for the segment profit of (3,596) million yen includes elimination of inter-segment transaction of 154
million yen and corporate cost of (3,750) million yen. Corporate cost consisted primarily of general andadministrative expenses and research and development cost which do not belong to the reporting segment.
Segment profit is adjusted to the operating income on the consolidated statements of income.

2.

Change in Reportable Segment
The reportable segment of Nipro Glass India Ltd. and Nipro Tube Glass Ltd. was changed from materials business to
medical business from the period ended March 30, 2012 as a result of reconsideration from the view point of global
business strategy.
Following this idea, the segment information of the same period of previous year was revised.

3.

Information about Impairment Loss of Tangible Assets and Goodwill by Reportable Operating Segment
N/A(6) Notes to Statements of Shareholder’s Equity, if having Significant Variation
N/A- 11 -